- Home
- OSK vs NUVL Comparison
OSK vs NUVL Comparison
Compare OSK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSK
- NUVL
- Stock Information
- Founded
- OSK 1917
- NUVL 2017
- Country
- OSK United States
- NUVL United States
- Employees
- OSK N/A
- NUVL N/A
- Industry
- OSK Auto Manufacturing
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- OSK Consumer Discretionary
- NUVL Health Care
- Exchange
- OSK Nasdaq
- NUVL Nasdaq
- Market Cap
- OSK 8.7B
- NUVL 7.2B
- IPO Year
- OSK N/A
- NUVL 2021
- Fundamental
- Price
- OSK $121.20
- NUVL $93.00
- Analyst Decision
- OSK Buy
- NUVL Strong Buy
- Analyst Count
- OSK 12
- NUVL 12
- Target Price
- OSK $145.25
- NUVL $123.33
- AVG Volume (30 Days)
- OSK 953.7K
- NUVL 596.8K
- Earning Date
- OSK 10-29-2025
- NUVL 10-30-2025
- Dividend Yield
- OSK 1.68%
- NUVL N/A
- EPS Growth
- OSK N/A
- NUVL N/A
- EPS
- OSK 10.25
- NUVL N/A
- Revenue
- OSK $10,331,600,000.00
- NUVL N/A
- Revenue This Year
- OSK N/A
- NUVL N/A
- Revenue Next Year
- OSK $5.40
- NUVL N/A
- P/E Ratio
- OSK $11.85
- NUVL N/A
- Revenue Growth
- OSK N/A
- NUVL N/A
- 52 Week Low
- OSK $76.82
- NUVL $55.54
- 52 Week High
- OSK $144.30
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- OSK 38.03
- NUVL 51.51
- Support Level
- OSK $118.53
- NUVL $89.38
- Resistance Level
- OSK $127.46
- NUVL $95.93
- Average True Range (ATR)
- OSK 4.48
- NUVL 5.08
- MACD
- OSK -1.15
- NUVL -0.86
- Stochastic Oscillator
- OSK 11.82
- NUVL 22.36
About OSK Oshkosh Corporation (Holding Company)Common Stock
Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.